Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3048% below fair value
$2.96−0.17 (-5.43%)
Close on Nov 12, 2026Market cap $238.49MP/E 11.8Yield –
Protalix BioTherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Protalix BioTherapeutics's operating margin for the twelve months ending Sep 30, 2026 was 29.8%. For fiscal 2025 it was -10.4%, against 7.3% the year before. The highest annual figure on record is 16.0% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -10.4% | −17.8 |
| FY2024 | Dec 31, 2024 | 7.3% | −8.6 |
| FY2023 | Dec 31, 2023 | 16.0% | +43.3 |
| FY2022 | Dec 31, 2022 | -27.3% | +26.0 |
| FY2021 | Dec 31, 2021 | -53.4% | −57.7 |
| FY2020 | Dec 31, 2020 | 4.3% | +23.9 |
| FY2019 | Dec 31, 2019 | -19.6% | +36.8 |
| FY2018 | Dec 31, 2018 | -56.4% | +107.4 |
| FY2017 | Dec 31, 2017 | -163.8% | +196.7 |
| FY2016 | Dec 31, 2016 | -360.5% | +181.9 |
| FY2015 | Dec 31, 2015 | -542.4% | +268.3 |
| FY2014 | Dec 31, 2014 | -810.6% | −775.7 |
| FY2012 | Dec 31, 2012 | -34.9% | +400.7 |
| FY2011 | Dec 31, 2011 | -435.6% | +15.5 |
| FY2010 | Dec 31, 2010 | -451.2% | +7788.3 |
| FY2009 | Dec 31, 2009 | -8239.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 18.5% | +6.5 |
| Q2 FY2026 | Jun 30, 2026 | 23.5% | +16.0 |
| Q1 FY2026 | Mar 31, 2026 | 62.7% | +103.6 |
| Q4 FY2025 | Dec 31, 2025 | -51.1% | −90.6 |
| Q3 FY2025 | Sep 30, 2025 | 11.9% | −10.3 |
| Q2 FY2025 | Jun 30, 2025 | 7.5% | +25.5 |
| Q1 FY2025 | Mar 31, 2025 | -41.0% | +88.6 |
| Q4 FY2024 | Dec 31, 2024 | 39.6% | +93.1 |
| Q3 FY2024 | Sep 30, 2024 | 22.2% | +40.5 |
| Q2 FY2024 | Jun 30, 2024 | -18.0% | −76.2 |
| Q1 FY2024 | Mar 31, 2024 | -129.6% | −103.9 |
| Q4 FY2023 | Dec 31, 2023 | -53.5% | −24.6 |
| Q3 FY2023 | Sep 30, 2023 | -18.2% | +3.8 |
| Q2 FY2023 | Jun 30, 2023 | 58.2% | +121.3 |
| Q1 FY2023 | Mar 31, 2023 | -25.6% | −14.0 |
| Q4 FY2022 | Dec 31, 2022 | -29.0% | +37.8 |
| Q3 FY2022 | Sep 30, 2022 | -22.0% | −6.4 |
| Q2 FY2022 | Jun 30, 2022 | -63.1% | +79.5 |
| Q1 FY2022 | Mar 31, 2022 | -11.6% | +21.1 |
| Q4 FY2021 | Dec 31, 2021 | -66.7% | −81.3 |
| Q3 FY2021 | Sep 30, 2021 | -15.6% | −37.3 |
| Q2 FY2021 | Jun 30, 2021 | -142.6% | −155.0 |
| Q1 FY2021 | Mar 31, 2021 | -32.7% | −21.9 |
| Q4 FY2020 | Dec 31, 2020 | 14.6% | +62.2 |
| Q1 FY2020 | Mar 31, 2020 | 21.7% | +74.7 |
| Q4 FY2019 | Dec 31, 2019 | 12.4% | +26.0 |
| Q3 FY2019 | Sep 30, 2019 | -10.8% | +553.4 |
| Q2 FY2019 | Jun 30, 2019 | -47.7% | +288.5 |
| Q1 FY2019 | Mar 31, 2019 | -53.0% | +60.1 |
| Q4 FY2018 | Dec 31, 2018 | -13.6% | +209.0 |
| Q3 FY2018 | Sep 30, 2018 | -564.3% | −461.1 |
| Q2 FY2018 | Jun 30, 2018 | -336.2% | −166.2 |
| Q1 FY2018 | Mar 31, 2018 | -113.1% | +107.2 |
| Q4 FY2017 | Dec 31, 2017 | -222.6% | +196.5 |
| Q3 FY2017 | Sep 30, 2017 | -103.2% | +39.2 |
| Q2 FY2017 | Jun 30, 2017 | -169.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -220.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -419.0% | – |
| Q3 FY2016 | Sep 30, 2016 | -142.4% | – |
See a number that looks wrong?